Last reviewed · How we verify
Cohort 1 Matching Sugar Capsule
At a glance
| Generic name | Cohort 1 Matching Sugar Capsule |
|---|---|
| Sponsor | OPKO Health, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Drug-drug Interaction Study of Gepotidacin (PHASE1)
- Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis (PHASE2)
- First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699 (PHASE1)
- CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) (PHASE1)
- Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cohort 1 Matching Sugar Capsule CI brief — competitive landscape report
- Cohort 1 Matching Sugar Capsule updates RSS · CI watch RSS
- OPKO Health, Inc. portfolio CI